Skip to main content
SpringerLink
Log in

Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

First-generation antihistamines taken for relief of allergic rhinitis are sedating and pose potential risks for those driving a car or operating machinery. Desloratadine is a potent, selective, histamine H1-receptor antagonist that does not easily cross the blood–brain barrier. It is nonsedating at therapeutic doses and should not affect driving or psychomotor performance.

Objective

This study compared the acute effects of desloratadine with diphenhydramine (active control) and placebo on the performance of healthy subjects evaluated with standard over-the-road driving tests (primary objective). The subjects’ performances were also evaluated (secondary objective) with the use of conventional performance tests.

Methods

Eighteen men and women received a single dose of desloratadine 5 mg, diphenhydramine 50 mg, or placebo during each period of this randomized, double-blind, three-way, crossover study. Two hours post-dosing, subjects operated a specially instrumented vehicle in a 90-min test designed to measure their ability (1) to maintain constant speed and lateral position while following another vehicle at a constant distance and (2) to respond to brake signals. Additionally, a full battery of performance tests was administered.

Results

No significant differences were noted between desloratadine and placebo in standard deviation of lateral position (SDLP), whereas diphenhydramine treatment significantly increased SDLP (P<0.001 for both comparisons). Brake reaction time was significantly faster following treatment with desloratadine than diphenhydramine (473.72 ms vs 541.22 ms; P<0.001) or placebo (512.06 ms; P=0.033). No differences were seen among treatments in deviation of speed or distance to the lead car. The majority of performance tests showed no significant differences among groups.

Conclusion

Desloratadine at a therapeutic dose does not impair driving performance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. O’Hanlon JF (1988) Antihistamines and driving safety. Cutis 42:10–13

    Google Scholar 

  2. Ramaekers JG, Uiterwijk MMC, O’Hanlon JF (1992) Effects of loratadine and cetirizine on actual driving and psychometric test performance and EEG during driving. Eur J Clin Pharmacol 42:363–369

    CAS  PubMed  Google Scholar 

  3. Volkerts ER, Van Laar M (1995) Specific review of the psychometric effects of cetirizine. Allergy 50:55–60

    CAS  Google Scholar 

  4. O’Hanlon JF, Ramaekers JG (1995) Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989–94. Allergy 50:234–242

    CAS  PubMed  Google Scholar 

  5. Wilken JA, Berkowitz R, Kane R (2002) Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 89:372–380

    PubMed  Google Scholar 

  6. Spaeth J, Klimek L, Mosges R (1996) Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 51:893–906

    CAS  PubMed  Google Scholar 

  7. Marshall PS, O’Hara C, Steinberg P (2000) Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol 84:403–410

    CAS  PubMed  Google Scholar 

  8. Simons FE, Simons KJ (1999) Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 36:329–352

    CAS  PubMed  Google Scholar 

  9. Simons FER (1999) H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 83:481–488

    Google Scholar 

  10. Kay GG, Quig ME (2001) Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc 22:281–283

    CAS  PubMed  Google Scholar 

  11. Salmun L, Lorber R (2002) 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract 3:14

    Article  PubMed  Google Scholar 

  12. Meltzer E, Prenner B, Nayak A, Desloratadine Study Group (2001) Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 21:25–32

    CAS  Google Scholar 

  13. Scadding GK (2002) Desloratadine in the treatment of nasal congestion in seasonal allergic rhinitis. Preclinical and clinical evidence. Clin Drug Invest 22[Suppl 2]:21–32

  14. Nayak AS, Schenkel E (2001) Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56:1077–1080

    Article  CAS  PubMed  Google Scholar 

  15. Simons FER, Prenner BM, Finn A (2003) Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 111:617–622

    Article  CAS  PubMed  Google Scholar 

  16. Bachert C, Virchow JC, Plenker A (2002) Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin Drug Invest 22[Suppl 2]:43–52

  17. Gupta S, Banfield C, Affrime M, Marco A, Cayen M, Herron J, Padhi D (2002) Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin Pharmacokinet 41[Suppl]:1–6

    Google Scholar 

  18. Nayak A, Salmun LM, Lorber RR (2000) Desloratadine relieves nasal congestion in patients with seasonal allergic rhinitis. Allergy 55[Suppl 63]:193–194

  19. Kreutner W, Hey JA, Chiu P, Barnett A (2000) Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1-receptor antagonist. Second communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 50:441–448

    CAS  PubMed  Google Scholar 

  20. Rikken G, Scharf MB, Danzig MR, Staudinger H (2000) Desloratadine and alcohol co-administration: no increase in impairment of performance over that induced by alcohol alone. Allergy 55[Suppl 63]:277

  21. O’Hanlon JF, Haak TW, Blaauw GJ, Riemersma JB (1982) Diazepam impairs lateral position control in highway driving. Science 217:79–81

    CAS  PubMed  Google Scholar 

  22. Vuurman EF, Muntjewerff ND, Uiterwijk MM, Van Veggel LM, Crevoisier C, Haglund L, Kinzig M, O’Hanlon JF (1996) Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 50:475–482

    Article  CAS  PubMed  Google Scholar 

  23. Ramaekers G, Lamers J, Verhey F, Muntjewerff D, Mobbs E, Sanders N, Lewis M, Lockton A (2002) A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic. Psychopharmacology 159:203–210

    Article  CAS  PubMed  Google Scholar 

  24. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC (1973) Quantification of sleepiness: a new approach. Psychophysiology 10:431–436

    CAS  PubMed  Google Scholar 

  25. Kapetyn TS, Bles W, Njiokiktjein CHJ, Kodde I, Massen CH, Mol JMF (1983) Standardization in platform stabilimetry being part of posturography. Agressology 24:321–326

    Google Scholar 

  26. Rey A (1964) L’examine physiologique dans le cas d’encephalopathie traumatique. Presse Universitaires de France, Paris

  27. Wechsler D (1981) The measurement and appraisal of adult intelligence. Williams and Wilkins, Baltimore

  28. Vuurman EF, Uiterwijk MM, Rosenzweig P, O’Hanlon JF (1994) Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 47:253–259

    CAS  PubMed  Google Scholar 

  29. Jex HR, McDonnell JD, Phatak AV (1966) A “critical” tracking task for manual control research. IEEE Trans Human Factors Electron 7:138–145

    Google Scholar 

  30. Moskowitz H, Burns M (1977) The effects of alcohol and valium, singly and in combination, upon driving-related skills performance. In: Hulke D (ed) Proceedings of the 21st conference of the American Association for Automotive Medicine. American Association of Automotive Medicine, Morton Grove, Illinois, pp 226–240

  31. Baddely AD (1968) A three-minute test based on grammatical transformation. Psychometric Science 72:257–269

    Google Scholar 

  32. Collins AM, Quillian MR (1969) Retrieval time from semantic memory. J Verbal Learn Verbal Behav 8:240–247

    Google Scholar 

  33. Brookhuis KA, De Vries G, De Waard D (1993) Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10-, 20-, and 30-mg dose, and triprolidine 10 mg on car driving performance. Br J Pharmacol 36:67–70

    CAS  Google Scholar 

  34. Vermeeren A, O’Hanlon JF (1998) Fexofenadine’s effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 101:306–311

    CAS  PubMed  Google Scholar 

  35. Weiler JM, Bloomfield JR, Woodworth GG, Grant AR, Layton TA, Brown TL, McKenzie DR, Baker TW, Watson GS (2000) Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 132:354–363

    Google Scholar 

  36. Volkerts ER, Van Willigenburg APP, Van Laar MW, Maes RAA (1992) Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance, and daytime sleepiness. Hum Psychopharmacol 7:227–238

    CAS  Google Scholar 

  37. Vermeeren A (2003) Hypnotics and antihistamines: effects on cognitive functions and driving performance (ISBN 90-75579-15-2). Thesis Neuropsych Publishers, Maastrict

    Google Scholar 

Download references

Acknowledgement

This study was supported by a research grant from Schering-Plough Research Institute, Kenilworth, New Jersey.

Author information

Authors and Affiliations

  1. Experimental Psychopharmacology Unit, Department of Psychiatry and Neuropsychology, P.O. Box 616, 6200 MD, Maastricht, the Netherlands

    E. F. P. M. Vuurman, N. D. Muntjewerff & J. G. Ramaekers

  2. Schering-Plough Research Institute, Kenilworth, New Jersey, United States

    G. H. Rikken & F. de Halleux

Authors
  1. E. F. P. M. Vuurman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. H. Rikken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. D. Muntjewerff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. de Halleux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. G. Ramaekers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. F. P. M. Vuurman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vuurman, E.F.P.M., Rikken, G.H., Muntjewerff, N.D. et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 60, 307–313 (2004). https://doi.org/10.1007/s00228-004-0757-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0757-9

Keywords

Search

Navigation